ANVS
Annovis BioยทNYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ANVS Profile
Annovis Bio, Inc.
A clinical-stage biotech company developing novel treatments for neurodegenerative diseases using its proprietary peptide-based technology
101 Lindenwood Drive, Suite 225, Malvern, PA 19355
--
Annovis Bio, Inc., was incorporated under the laws of the State of Delaware on April 29, 2008. Annovis is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of Parkinson's disease (" PD ") and Alzheimer's disease (" AD ") and neurodegenerative diseases. The company's lead compound, ANVS-401, is a neurochemical nerve defect therapy that inhibits neurodegeneration and inhibits the conversion of neurotoxic proteins into adults and normalized axonal vesicle transport.
